Overview

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

Status:
RECRUITING

Trial end date:
2030-01-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

Phase:

PHASE2

Details

Lead Sponsor:

The University of Texas Health Science Center, Houston

Treatments:

Endosonography
Immunotherapy
Neoadjuvant Therapy
pembrolizumab